# Clopidose trial

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
24/01/2006	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
27/01/2006	Completed	Results
Last Edited	Condition category	Individual participant data
14/02/2008	Circulatory System	Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

## Type(s)

Scientific

#### Contact name

Prof François Mach

#### Contact details

Geneva University Hospital
Cardiology Division
24 Micheli-du-Crest
Geneva
Switzerland
1211
+41 (0)22 382 7234
francois.mach@medecine.unige.ch

## Additional identifiers

**Protocol serial number** N/A

# Study information

Scientific Title

**Study objectives** 

150 mg/day maintenance dose will increase the biological effect of clopidogrel in clopidogrel low responders

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

This protocol has been approved by the ethics committee of the internal medicine department in November 2005

### Study design

Open labelled clinical study with patients admitted for coronary angioplasty

### Primary study design

Interventional

### Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Cardiovascular outpatients

#### **Interventions**

After a loading dose of clopidogrel (600 mg), patients will take a standard dose of clopidogrel 75 mg once a day for 15 days.

At day 15, adenosine diphosphate (ADP) induced platelet aggregation and measurement of phosphorylated vasodilator-stimulated phosphoprotein (VASP-P) by a flow cytometric technique will be performed. If patients are clopidogrel resistant, they will receive 150 mg (2x75) once a day during the next 15 days. ADP-induced platelet aggregation and measurement of VASP-P will be performed at day 30.

## Intervention Type

Drug

#### Phase

**Not Specified** 

## Drug/device/biological/vaccine name(s)

Clopidogrel

## Primary outcome(s)

Biological effect of clopidogrel

## Key secondary outcome(s))

Genetic association study

## Completion date

30/12/2006

## **Eligibility**

## Key inclusion criteria

Cardiovascular outpatients on 75 mg/day clopidogrel

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

## Age group

**Not Specified** 

#### Sex

**Not Specified** 

### Key exclusion criteria

Anticoagulation

#### Date of first enrolment

01/12/2005

#### Date of final enrolment

30/12/2006

## **Locations**

#### Countries of recruitment

**Switzerland** 

## Study participating centre Geneva University Hospital

Geneva Switzerland 1211

## Sponsor information

## Organisation

Geneva University Hospital (Switzerland)

#### **ROR**

https://ror.org/01m1pv723

# Funder(s)

## Funder type

University/education

#### Funder Name

University of Geneva Cardiology Foundation (GECOR)

#### Funder Name

Geneva University Hospital Internal Medicine Department

## **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration